Clinical TrialJul 24, 2026, 12:07 PM
Profound Medical TULSA Procedure Superior in Penile Length Preservation
AI Summary
Profound Medical Corp. announced new data from its Level 1 post-market CAPTAIN randomized controlled trial, comparing the TULSA Procedure with robotic radical prostatectomy for prostate cancer. The TULSA Procedure demonstrated statistically significant superiority in preserving penile length, showing no median change at one month compared to a 0.65 cm reduction with robotic RP. These findings add to previously announced results where TULSA showed superior preservation of erectile function and urinary continence.
Key Highlights
- TULSA Procedure showed no median change in penile length at 1 month.
- Robotic RP resulted in a median 0.65 cm reduction in penile length at 1 month.
- Statistically significant difference of 0.42 cm (p<0.001) in penile length change.
- TULSA previously demonstrated superior erectile function and urinary continence at 6 months.
- CAPTAIN trial enrolled 211 patients across 23 sites in US, Canada, and Europe.
Price Impact
More from PROF